COMMUNIQUÉS West-GlobeNewswire

-
Theratechnologies présente ses résultats financiers pour le deuxième trimestre de 2025
09/07/2025 -
Theratechnologies Reports Financial Results for the Second Quarter 2025
09/07/2025 -
Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)
09/07/2025 -
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
09/07/2025 -
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
09/07/2025 -
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
09/07/2025 -
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
09/07/2025 -
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
09/07/2025 -
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
09/07/2025 -
MEME Coins Inc. Finalizes DOG Token Acquisition from Tipestry Inc.
09/07/2025 -
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland
09/07/2025 -
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
09/07/2025 -
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
09/07/2025 -
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
09/07/2025 -
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity
08/07/2025 -
LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025
08/07/2025 -
Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering
08/07/2025 -
RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance
08/07/2025 -
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
08/07/2025
Pages